Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tetracaine + oxymetazoline is a combination drug consisting of a local anesthetic and a vasoconstrictor, being evaluated by the Louisiana State University Health Sciences Center in New Orleans for needle-free dental anesthesia. Tetracaine is an ester-type local anesthetic that works by inhibiting voltage-gated sodium ion channels, thereby blocking nerve impulse conduction. Oxymetazoline is a sympathomimetic amine that acts as an alpha-adrenergic agonist, causing local vasoconstriction which helps to localize the anesthetic and reduce systemic absorption. In this specific application, the combination is delivered to the oral mucosa using iontophoresis, a technique that uses a low-level electrical current to enhance the transmucosal delivery of ionized drugs, providing a non-invasive alternative to traditional syringe-based local anesthesia for dental procedures.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tetracaine + oxymetazoline.